Journal Mobile Options
Table of Contents
Vol. 25, No. 2-4, 2003
Issue release date: March–August (September 2003)
Section title: Paper
Dev Neurosci 2003;25:96–104
(DOI:10.1159/000072259)

Soma-Restricted Products of the Myelin Proteolipid Gene Are Expressed Primarily in Neurons in the Developing Mouse Nervous System

Jacobs E.C. · Bongarzone E.R. · Campagnoni C.W. · Kampf K. · Campagnoni A.T.
aDevelopmental and Molecular Neuroscience Group, Neuropsychiatric Institute and bBrain Research Institute, UCLA School of Medicine, Los Angeles, Calif., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 9.00
Account: USD 8.00

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Received: 3/21/2003
Accepted: 4/1/2003
Published online: 9/15/2003

Number of Print Pages: 9
Number of Figures: 6
Number of Tables: 1

ISSN: 0378-5866 (Print)
eISSN: 1421-9859 (Online)

For additional information: http://www.karger.com/DNE

Abstract

The myelin proteolipid gene encodes two sets of proteins, the classic PLP and DM20 and the sr (soma-restricted)-PLP and sr-DM20. Unlike the classic proteolipids, the sr-products are expressed in both neurons and oligodendrocytes (OLs) and are not components of the myelin sheath. In OLs, the sr-isoforms are associated with endosomes and recycling vesicles indicating a possible nonmyelin function for these proteins. In this study, a purified antibody specific for the sr-products was used to examine the expression of these proteins during the development of the mouse brain. We found that while sr-PLP and sr-DM20 are expressed in OLs, the highest levels of immunoreactivity were found in neuronal populations. During early embryonic development (E13–E15), sr-proteolipids were detected in the dorsal root ganglion and motor neurons in the spinal cord. By E17, immunostaining for sr-PLP and sr-DM20 in the brain increased dramatically. The highest levels of immunoreactivity were found during the first and second weeks postnatal after which staining intensity declined to adult levels and the pattern of expression was more restricted. Robust staining persisted in many neuronal populations including nuclei in the hindbrain, Purkinje and granule neurons in the cerebellum, pyramidal cells in the cortex and mitral cells in the olfactory bulb. The spatial and temporal pattern of sr-PLP and sr-DM20 expression is very similar to that of the endosomal protein, syntaxin 13, consistent with the finding that the sr-PLPs may play a role in vesicular transport in neurons.


Article / Publication Details

First-Page Preview
Abstract of Paper

Received: 3/21/2003
Accepted: 4/1/2003
Published online: 9/15/2003

Number of Print Pages: 9
Number of Figures: 6
Number of Tables: 1

ISSN: 0378-5866 (Print)
eISSN: 1421-9859 (Online)

For additional information: http://www.karger.com/DNE


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.